What Enanta Pharmaceuticals does

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunological diseases. Founded in 1995 and headquartered in Watertown, Massachusetts, the company operates with fewer than 200 employees and trades on NASDAQ under ticker ENTA. Enanta's research is anchored in medicinal chemistry and has historically focused on protease inhibitors, exemplified by the discovery of glecaprevir and paritaprevir — compounds commercialized by AbbVie in the HCV regimens MAVYRET/MAVIRET and VIEKIRA PAK, which have collectively cured more than one million patients.

The company's clinical pipeline spans multiple mechanisms of action: RSV antivirals (zelicapavir, an N-protein inhibitor advancing to registrational Phase 2b/3; and EDP-323, an L-protein inhibitor with Phase 2a data), a COVID-19 candidate (EDP-235, a 3CL protease inhibitor), an HBV core inhibitor (EDP-514), and an expanding immunology franchise (EDP-978, an oral KIT inhibitor in Phase 1; EPS-3903, a STAT6 inhibitor in IND-enabling studies; and MRGPRX2 inhibitors in discovery). Four candidates hold FDA Fast Track designation, supporting expedited development pathways.

Enanta's business model is dual-track. Revenue is generated almost entirely through royalty payments from AbbVie on worldwide sales of MAVYRET/MAVIRET — approximately $18.6 million in Q1 FY2026 — providing a cash-generative base that has historically delivered over $1 billion in non-dilutive financing through the AbbVie collaboration. The company is advancing pipeline assets toward registrational milestones with the intent of securing new commercialization partnerships or building independent sales capability for future launches. An October 2025 upsized public offering raised $74.75 million, extending the cash position to $241.9 million as of December 31, 2025 and funding operations into fiscal 2029. The company also retains optionality on pipeline assets via a dedicated business development function and historical collaborations with Novartis, Shionogi, and government funders.

Name

Enanta Pharmaceuticals

Legal name

Enanta Pharmaceuticals, Inc.

Website

https://enanta.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

101–250 employees

Short description

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunology, generating royalty revenue from AbbVie's hepatitis C treatments while advancing a pipeline in RSV, HBV, and inflammatory diseases.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Small molecule drug discovery
• Antiviral therapeutics
• Hepatitis C treatment
• RSV drug development
• Immunology drug development

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Royalty Payments from AbbVie: Enanta receives ongoing royalty payments from AbbVie based on sales of MAVYRET/MAVIRET (glecaprevir/pibrentasvir) for hepatitis C treatment. Revenue was $18.6 million in fiscal Q1 2026 (quarter ended December 31, 2025), up from $17.0 million in the prior year period.
2. Public Stock Offering: Enanta raised approximately $74.75 million through an upsized public offering of 7,475,000 shares of common stock at $10.00 per share in October 2025 to fund clinical trials, research, and development, and general corporate purposes.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers, develops, and commercializes small molecule drugs for viral infections (HCV, RSV, HBV, COVID-19) and immunological diseases. Its marketed products (glecaprevir and paritaprevir, used in AbbVie's MAVYRET/MAVIRET and VIEKIRA PAK regimens for hepatitis C) are commercialized by AbbVie under a longstanding collaboration that has cured over one million patients. The company's clinical pipeline includes zelicapavir and EDP-323 for RSV, EDP-235 for COVID-19, EDP-514 for HBV, and EDP-978, EPS-3903, and MRGPRX2 inhibitors for immunology indications.

Product overview

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on small molecule drug discovery and development for viral infections and immunological diseases. The company's product portfolio includes marketed hepatitis C virus treatments (glecaprevir/MAVYRET and paritaprevir/VIEKIRA PAK, commercialized by AbbVie), clinical-stage RSV antivirals (zelicapavir and EDP-323 with Fast Track designation), COVID-19 treatment candidate (EDP-235), and an expanding immunology pipeline targeting type 2 inflammatory diseases including KIT inhibitor EDP-978 (Phase 1 for chronic urticaria), STAT6 inhibitor EPS-3903 (preclinical for atopic dermatitis), and MRGPRX2 inhibitors (discovery stage). The company also has a hepatitis B virus candidate (EDP-514, Fast Track designated) in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Glecaprevir (MAVYRET/MAVIRET) Protease inhibitor co-formulated with pibrentasvir as AbbVie's direct-acting antiviral combination treatment for hepatitis C virus, discovered by Enanta and commercialized by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.). The only 8-week cure for HCV, approved for both acute and chronic HCV.
• Paritaprevir (VIEKIRA PAK) Protease inhibitor developed through Enanta's collaboration with AbbVie, included in fixed-dose combinations with other direct-acting antivirals for treatment of selected HCV genotypes, commercialized by AbbVie as VIEKIRA PAK (U.S.) and VIEKIRAX (ex-U.S.).
• Zelicapavir (EDP-938) Oral N-protein inhibitor for respiratory syncytial virus (RSV) treatment, dosed in more than 700 people with favorable safety profile. Phase 2b/3 registrational trial for high-risk adults planned. Has FDA Fast Track designation.
• EDP-323 Oral L-protein inhibitor targeting RSV polymerase for treatment of respiratory syncytial virus with sub-nanomolar potency in vitro. Has FDA Fast Track designation. Completed Phase 2a challenge study showing statistically significant reductions in viral load and symptoms.
• EDP-235 Oral 3CL protease inhibitor (3CLpro) for treatment of COVID-19 with nanomolar activity against all SARS-CoV-2 variants and potent antiviral activity against other human coronaviruses. Has FDA Fast Track designation. Completed Phase 2 SPRINT study.
• EDP-514 Novel core inhibitor (capsid assembly modulator) for hepatitis B virus (HBV) treatment that disrupts assembly and replication of HBV at multiple steps in viral life cycle. Has FDA Fast Track designation. Phase 1 studies completed with robust antiviral activity.
• EDP-978 Oral once-daily KIT inhibitor for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases with potent nanomolar activity. Phase 1 trial initiated with topline data expected Q4 2026.
• EPS-3903 Selective oral STAT6 inhibitor for atopic dermatitis and other Th2 inflammatory diseases with nanomolar potency and high selectivity over other STATs. Offers potential as 'oral dupilumab' by directly blocking IL-4/IL-13 signaling. IND-enabling activities ongoing.
• MRGPRX2 Inhibitors Oral inhibitors targeting MRGPRX2 receptor expressed on mast cells for chronic spontaneous urticaria and atopic dermatitis with nanomolar potency in cellular assays. Multiple compounds in preclinical evaluation.

Quantifiable outcome

• 96.2% sustained virological response rate at 12 weeks (SVR12) for MAVIRET in acute HCV Phase 3 clinical trial
• +5 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core, minor and flagship.

• Penta FoundationcoreStrategic or Co-development Partner · 18 June 2026Collaboration for a Phase 2b pediatric clinical trial of zelicapavir in RSV patients aged 28 days to 36 months, with topline data expected in 2027. The Penta Foundation is a well-established pediatric research network.
• Chiang Mai University's AMS-PHPT Research UnitcoreStrategic or Co-development Partner · 18 June 2026Collaboration for Phase 2b pediatric RSV trial in Thailand as part of Enanta's global pediatric development program for zelicapavir, with data expected in 2027.
• NovartisminorStrategic or Co-development Partner · 1 February 2012In February 2012, Enanta entered into an exclusive collaboration and license agreement with Novartis for worldwide development, manufacture and commercialization of its lead development candidate EDP-239 from its NS5A HCV inhibitor program.
• AbbVieflagshipStrategic or Co-development Partner · 1 November 2006In November 2006, Enanta entered into a Collaborative Development and License Agreement with Abbott (later AbbVie) to identify, develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. This partnership led to FDA approval of VIEKIRA PAK (2014) and MAVYRET (2017), which have cured over one million patients globally. AbbVie is responsible for all worldwide marketing and sales, with Enanta receiving ongoing royalty payments.
• ShionogiminorStrategic or Co-development Partner · 1 July 2004In July 2004, Enanta entered into an agreement with Shionogi to develop and commercialize an antibiotic (EDP-420) for the treatment of community-acquired pneumonia and community respiratory tract infections.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Assembly Biosciences: Assembly Biosciences is a clinical-stage biotechnology company developing small molecule therapies for chronic hepatitis B virus infection, including core inhibitors and other mechanisms that directly overlap with Enanta's EDP-514 HBV core inhibitor program.
• Aligos Therapeutics: Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B and other liver diseases, with capsid inhibitors and other small molecule candidates that directly compete with Enanta's EDP-514 in the HBV space.
• Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing antiviral therapies for serious infectious diseases, including RSV, hepatitis B, and influenza. Vir's broad antiviral pipeline and focus on small molecule and antibody approaches for respiratory viruses makes it a direct competitor to Enanta's RSV and HBV programs.
• Cocrystal Pharma: Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics for norovirus, influenza, COVID-19, and hepatitis B using structure-based drug design. The company shares Enanta's small molecule approach to viral diseases, including direct overlap in HBV and coronaviruses.
• Arbutus Biopharma: Arbutus Biopharma is a clinical-stage biopharmaceutical company developing small molecule oral therapies for chronic Hepatitis B virus infection. Like Enanta, it targets HBV with novel mechanisms (capsid inhibitors, RNAi), competing for the same patient population with similar small-molecule chemistry approaches.
• Atea Pharmaceuticals: Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral therapeutics, notably for COVID-19 (3CL protease inhibitors similar to Enanta's EDP-235) and hepatitis C. Atea's direct overlap in 3CL protease chemistry and HCV development makes it a highly relevant peer.
• Eiger BioPharmaceuticals: Eiger BioPharmaceuticals developed small molecule therapies for hepatitis B and hepatitis D viruses, including lonafarnib for HDV. As a small-cap antiviral company targeting hepatitis with oral therapies, Eiger has been a direct peer to Enanta in the HBV/HDV space.

Emerging players

• Brii Biosciences: Brii Biosciences is a clinical-stage biopharmaceutical company developing therapeutics for infectious diseases and central nervous system disorders, with a portfolio that includes HBV functional cure programs. The company has partial overlap with Enanta in HBV and broader infectious disease focus.

Others

• AbbVie: AbbVie is Enanta's most important commercial partner and the global marketer of MAVYRET/MAVIRET and VIEKIRA PAK containing Enanta's discovered protease inhibitors. While not a direct competitive peer, AbbVie is the ecosystem participant that has commercialized Enanta's discoveries and continues to pay royalties, making the relationship economically defining for Enanta.

Broad incumbents

• Gilead Sciences: Gilead Sciences is the dominant global player in HIV and HCV treatment (with HCV franchises including Harvoni, Sovaldi, Epclusa) and also develops antivirals in HBV and respiratory viruses. As the established incumbent in the antiviral space that Enanta helped advance through AbbVie's MAVYRET, Gilead represents the competitive benchmark for hepatitis antivirals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EnantaPharma
• LinkedInlinkedin.com/company/enanta-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enanta Pharmaceuticals